Literature DB >> 2789952

Tumour marker antigens during menses and pregnancy.

Y Touitou1, Y Darbois, A Bogdan, A Auzéby, S Keusseoglou.   

Abstract

Mesh：

Substances：

Year:  1989        PMID： 2789952      PMCID： PMC2247203          DOI： 10.1038/bjc.1989.297

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  6 in total

Review 1.  [Critical study of current tumoral markers].

Authors:  Y Touitou; A Bogdan
Journal:  Bull Cancer       Date:  1988       Impact factor: 1.276

2.  Serum CA-125 antigen levels increase during menses.

Authors:  D E Pittaway; J A Fayez
Journal:  Am J Obstet Gynecol       Date:  1987-01       Impact factor: 8.661

3.  CA-125 serum concentrations during the menstrual cycle.

Authors:  W Jäger; C Meier; L Wildt; W Sauerbrei; N Lang
Journal:  Fertil Steril       Date:  1988-08       Impact factor: 7.329

Review 4.  Tumor markers in non-malignant diseases.

Authors:  Y Touitou; A Bogdan
Journal:  Eur J Cancer Clin Oncol       Date:  1988-07

5.  Ovarian cancer antigen CA 125 levels in pelvic inflammatory disease and pregnancy.

Authors:  H Halila; U H Stenman; M Seppälä
Journal:  Cancer       Date:  1986-04-01       Impact factor: 6.860

6.  CA125 antigen levels in obstetric and gynecologic patients.

Authors:  J M Niloff; R C Knapp; E Schaetzl; C Reynolds; R C Bast
Journal:  Obstet Gynecol       Date:  1984-11       Impact factor: 7.661
  6 in total
  7 in total

1.  Ovarian torsion caused by hyperreactio luteinalis in the third trimester of pregnancy: a case report.

Authors:  Qin Li; Xiaotian Li; Pengnan Zhang
Journal:  Int J Clin Exp Med       Date:  2015-10-15

2.  Cervical cancer in pregnant women: treat, wait or interrupt? Assessment of current clinical guidelines, innovations and controversies.

Authors:  Sileny N Han; Mina Mhallem Gziri; Kristel Van Calsteren; Frédéric Amant
Journal:  Ther Adv Med Oncol       Date:  2013-07       Impact factor: 8.168

3.  Measurement of four tumor marker antigens in the sera of pregnant women.

Authors:  C D Cheli; D L Morris; I E Neaman; J Dai; W J Allard; K K Yeung
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

4.  CA15-3, CASA, MSA, and TPS as diagnostic serum markers in breast cancer.

Authors:  P L Devine; M A Duroux; R J Quin; M A McGuckin; G J Joy; B G Ward; C W Pollard
Journal:  Breast Cancer Res Treat       Date:  1995-06       Impact factor: 4.872

5.  Physiologic variations of serum tumor markers in gynecological malignancies during pregnancy: a systematic review.

Authors:  Sileny N Han; Anouk Lotgerink; Mina Mhallem Gziri; Kristel Van Calsteren; Myriam Hanssens; Frédéric Amant
Journal:  BMC Med       Date:  2012-08-08       Impact factor: 8.775

6.  Cancers Screening in an Asymptomatic Population by Using Multiple Tumour Markers.

Authors:  Hsin-Yao Wang; Chia-Hsun Hsieh; Chiao-Ni Wen; Ying-Hao Wen; Chun-Hsien Chen; Jang-Jih Lu
Journal:  PLoS One       Date:  2016-06-29       Impact factor: 3.240

7.  Can we trust tumour markers in pregnancy after breast cancer? A case of elevated CA 15-3 in the third trimester of pregnancy normalising after delivery.

Authors:  Barbara Buonomo; Stefania A Noli; Alessandra Santini; Carlo Alviggi; Fedro A Peccatori
Journal:  Ecancermedicalscience       Date:  2019-11-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.